Acasti Pharma Inc. — Form 10-Q summary
Entity and period: The supplied filing is for Acasti Pharma Inc., not Grace Therapeutics, Inc. It covers the quarter and six months ended September 30, 2023; amounts are in U.S. dollars unless noted. The company develops therapies for rare and orphan diseases and is prioritizing lead candidate GTX-104. It reports no product revenue and expects none until development and regulatory approval, if achieved.
Financial results and liquidity
| Metric | Three months ended Sep. 30, 2023 | Six months ended Sep. 30, 2023 | Comparable 2022 period |
|---|---|---|---|
| Revenue | None reported | None reported | None reported |
| Research and development expense | $460,000 | $1.555 million | $3.292 million and $5.882 million |
| General and administrative expense | $1.589 million | $3.352 million | $1.680 million and $3.599 million |
| Operating loss | $2.092 million | $6.546 million | $5.108 million and $9.838 million |
| Net loss | $3.273 million | $7.296 million | $4.929 million and $9.453 million |
| Loss per share | $0.43 | $0.97 | $0.66 and $1.28 |
| Operating cash used | Not stated for quarter | $8.353 million | $8.865 million for six months |
At September 30, cash and cash equivalents were $26.991 million, including $10.596 million cash and $16.395 million cash equivalents; short-term investments were $15,000. Current assets totaled $28.887 million, against current liabilities of $1.397 million. Total liabilities were $11.465 million, including $3.457 million of derivative warrant liabilities and $6.611 million of deferred tax liabilities. The filing reports no long-term debt. Total assets were $78.210 million and shareholders’ equity was $66.745 million. Operating margins are not meaningful given the absence of revenue.
Changes and financing
- Net loss narrowed year over year for both the quarter and six-month period, primarily alongside lower R&D spending after the company deprioritized GTX-101 and GTX-102 and reduced its workforce. The six-month results included $1.485 million of restructuring costs.
- Six-month operating cash use was $8.353 million, versus $8.865 million a year earlier. Cash declined $884,000 from March 31, 2023, after operating outflows were partly offset by financing proceeds.
- A September private placement generated approximately $7.3 million net proceeds. It included 1,951,371 common shares, 2,106,853 pre-funded warrants and 2,536,391 common warrants. The common warrants are liability-classified; their fair value increase generated a $1.826 million expense during the six months.
- Common shares outstanding increased from 7,435,533 at March 31 to 9,399,404 at September 30. The company also implemented a 1-for-6 reverse split in July and regained compliance with Nasdaq’s minimum bid-price rule.
Outlook, risks and unusual items
- Management estimates the cash runway, including private-placement proceeds, extends into the second calendar quarter of 2026, but says additional capital will be needed thereafter. The company has no committed financing source and may seek equity, debt or collaboration funding.
- The first patient entered the GTX-104 STRIVE-ON Phase 3 safety trial on October 23, 2023, after the quarter. The planned trial is approximately 100 patients; management expects it to take about 18 months from first enrollment and describes it as the final clinical step it expects to require before seeking FDA approval under the 505(b)(2) pathway. Approval and timing remain uncertain.
- GTX-102 and GTX-101 development is deferred pending funding or partnerships; management estimates the delay could be at least three years. The company recorded no further intangible-asset impairment in the six months ended September 30, 2023.
- The company disclosed approximately $8.5 million of CRO commitments for the next 12 months and no CMO commitments. Its former CaPre krill-oil supply dispute was settled on October 18, 2023: Aker BioMarine received the CaPre-related product, equipment, study data and intellectual property in exchange for releasing potential claims. The filing does not state a cash settlement payment.
- Other key risks include clinical-trial failure or delay, reliance on GTX-104, need for further financing, third-party manufacturing and CRO dependence, regulatory and reimbursement uncertainty, and potential dilution. Management reported disclosure controls were effective as of September 30, 2023.
Important facts for investors to verify
- Whether the reported cash runway assumptions remain achievable given the trial’s actual enrollment, CRO commitments and ongoing cash burn.
- STRIVE-ON enrollment, safety findings, completion timing and FDA requirements before an NDA submission.
- The potential dilution and accounting impact of the pre-funded and common warrants, including the warrant terms linked to FDA acceptance of a GTX-104 NDA.
- The terms and financial consequences of the CaPre settlement, and whether any obligations or effects beyond those described emerge.
- The availability and terms of future financing, and whether GTX-102 or GTX-101 can be funded or partnered without materially impairing GTX-104 development.